Blue Water Biotech, Inc.

As of August 29, 2024, Blue Water Biotech, Inc. is rated as risky due to significant losses and poor financial metrics, including a Price to Book Value of 0.11 and negative EV ratios, despite a volatile stock performance showing a year-to-date return of 376.19%, which is much higher than the S&P 500's 12.22%, but a one-year return of -36.44% compared to the S&P's 17.14%.

As of August 29, 2024, Blue Water Biotech, Inc. is rated as risky and overvalued, with poor financial ratios and a one-year stock return of -34.92%, significantly underperforming the S&P 500's 10.26% return.

As of May 1, 2025, Blue Water Biotech, Inc. shows a mildly bearish trend with mixed indicators, including bullish weekly MACD and bearish RSI readings, suggesting potential upward momentum but overall cautious sentiment.

Blue Water Biotech, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $29 million as of December 2024. Key metrics include a market cap of $0.70 million, a debt-to-equity ratio of 1.83, and a return on equity of -184.29%.

As of Jun 18, Blue Water Biotech, Inc. has a market capitalization of 0.70 million and reported net sales of 2.52 million with a net profit of -58.70 million over the latest four quarters.